Increased patient comfort utilizing botulinum toxin type A reconstituted with preserved versus nonpreserved saline

Ophthalmic Plastic and Reconstructive Surgery

Volumn 20, Issue 3, 2004, Pages 186-189

  Kwiat, David M ^a   Bersani, Thomas A ^b,d   Bersani, Adam ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c Manlius Pebble Hill School   (United States)

^d Eye Plast/Reconstruc Surg of CNY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; SODIUM CHLORIDE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; HUMAN; INJECTION PAIN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; HUMANS; NEUROMUSCULAR AGENTS; PAIN; PRESERVATIVES, PHARMACEUTICAL; SODIUM CHLORIDE;

EID: 2542504275     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.IOP.0000129012.09632.49     Document Type: Article

References (20)

1. Carruthers A, Carruthers J. History of the cosmetic use of botulinum toxin A exotoxin. Dermatol Surg 1998;24:1168-70.
2. Keith D. Pain associated with injection using frozen vs room-temperature needles. JAMA 2001;286:1578.
3. Edelstein C, Shorr N, Jacobs J, et al. Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998; 24:1208-12.
4. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg 1998;24:1179-80.
5. Alam M, Dover J, Arndt K. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative. Arch Dermatol 2002;138:510-4.
6. Littman GS, Walker BR, Schneider BE. Reassessment of verbal and visual analogue ratings in analgesic studies. Clin Pharmacol Ther 1985;38:16-23.
7. Yuen VH, Dolman PJ. Comparison of three modified lidocaine solutions for use in eyelid anesthesia. Ophthal Plast Reconstr Surg 1999;15:143-7.
8. Patterson P, Hussa AA, Fedele KA, et al. Comparison of 4 analgesic agents for venipuncture. AANA J 2000;68:43-51.
9. Farley JS, Hustead RF, Becker KE. Diluting lidocaine and mepivacaine in balanced salt solution reduces the pain of intradermal injection. Regional Anesth 1994;19:48-51.
10. Macht D. A pharmacological and therapeutic study of benzyl alcohol as a local anesthetic. J Pharmacol Toxicol Methods 1918: 11:263-79.
11. Hutchinson BT, Hyslop PA, Kuhn CE, et al. Sensitivity of adipocyte basal and insulin-stimulated hexose transport to the membrane lipid structure. Biochem Pharmacol 1985;34:1079-86.
12. Material Safety Data Sheet: Benzyl alcohol. Physchem.ox.ac.uk
13. Nair B. Final report on the safety assessment of benzyl alcohol, benzoic acid and sodium benzoate. Int J Toxicol 2001;20(Suppl 3):23-50.
14. Wilson L, Martin S. Benzyl alcohol as an alternative local anesthetic. Ann Emerg Med 1999;33:495-9.
15. Fein JA, Boardman CR, Stevenson S, et al. Saline with benzyl alcohol as intradermal anesthesia for intravenous line placement in children. Pediatr Emerg Care 1998;14:119-22.
16. McNelis KA. Intradermal bacteriostatic 0.9% sodium chloride containing the preservative benzyl alcohol compared with intradermal lidocaine hydrochloride 1% for attenuation of intravenous cannulation pain. J Am Assoc Nurse Anesthetists 1998:66:583-5.
17. Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex (Package Insert). Allergan Inc., Irvine, California, U.S.A. May 2003.
18. Gartlan GG, Hoffman HT. Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage. Otolaryngol Head Neck Surg 1993;108:135-40.
19. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology 1997;48:249-53.
20. Garcia A, Fulton JE. Cosmetic denervation of the muscles of facial expression with botulinum toxin. Dermatol Surg 1996;22:39-43.